Ultime notizie per Evotec (NASDAQ:EVO) Azioni

Evotec

Eaton Vance Ohio Municipal Income Trust Shares of Beneficial Interest

Eaton Vance Ohio Municip

Eaton Vance Ohio

Eaton Vance Ohio Municipal Income Trust

AMEX

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec SE

EVO TRANSPORTATION by EVO Transportation & Energy Services, Inc.

EVO Transportation & Energy Services Inc

EVOAIR HOLDINGS INC by EvoAir Holdings Inc.

EvoAir Holdings Inc

EvoAir Holdings Inc Ordinary Shares

Evoke Pharma Inc

SYMBOLIC LOGIC INC by Symbolic Logic Inc.

Symbolic Logic Inc

U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Wednesday.
Shares of Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected third-quarter financial results and issued FY24 revenue <a href="https://www.benzinga.com/general/biotech/24/11/41760212/exact-sciences-stock-plummets-after-worse-than-expected-q3-results-fy24-guidance-below-estimates">guidance below estimates</a>.
Exact Sciences reported quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million missed the consensus estimate of $717.66 million.
Exact Sciences shares dipped 27% to $52.20 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) fell 24.3% to $20.97 in pre-market trading after the company lowered its financial outlook. The company expects to report first-quarter revenue of $5.9 billion to $6 billion, down from its previous guidance range of $6 billion to $7 billion. The company anticipates adjusted earnings of 75 cents to 76 cents per share, versus its previous guidance of 67 cents to 83 cents per share.</li>
<li>Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) fell 20.8% to $1.86 in today's pre-market trading.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) fell 20.1% to $5.64 in pre-market trading after gaining 8% on Tuesday.</li>
<li>PACS Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) shares fell 18.8% to $24.00 in pre-market trading after the company announced postponement of third-quarter results and disclosure on civil investigative demands from the federal government.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) fell 18.6% to $13.76 in pre-market trading after gaining 5% on Tuesday.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) declined 16.8% to $3.81 in pre-market trading following weak quarterly results.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) shares fell 16.8% to $15.25 in pre-market trading.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) shares fell 14.7% to $184.00 in pre-market trading.</li>
<li>The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) declined 9.9% to $13.97 in pre-market trading.</li>
<li>Honda Motor Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) shares fell 7.4% to $28.05 in pre-market trading as the company said profits fell around 20% in the first half of the fiscal year.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

EXAS

FSLR

GEVO

NOVA

OSCR

PACS

SMCI

Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) stock increased by 16.6% to $10.4 during Wednesday's pre-market session. The market value of their outstanding shares is at $514.0 million. As per the press release, Q3 earnings came out today. </li>
<li>Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) shares increased by 15.83% to $6.0. The market value of their outstanding shares is at $642.8 million. </li>
<li>Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) shares increased by 15.11% to $4.34. The company's market cap stands at $272.2 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Xylo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XYLO#NASDAQ">XYLO</a>) stock rose 14.4% to $3.97. The market value of their outstanding shares is at $7.5 million. </li>
<li>Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) shares moved upwards by 13.77% to $85.99. The market value of their outstanding shares is at $11.6 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock increased by 13.63% to $1.25. The company's market cap stands at $4.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock decreased by 26.6% to $52.5 during Wednesday's pre-market session. The company's market cap stands at $9.7 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares declined by 24.53% to $0.1. The company's market cap stands at $1.7 million. </li>
<li>Altamira Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>) stock declined by 21.16% to $0.41. The market value of their outstanding shares is at $1.5 million. </li>
<li>PACS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) shares decreased by 20.49% to $23.49. The market value of their outstanding shares is at $3.6 billion. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) stock fell 19.66% to $3.68. The company's market cap stands at $1.3 billion. As per the press release, Q3 earnings came out today. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares declined by 15.93% to $0.41. The market value of their outstanding shares is at $5.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

BNOX

CYTO

GMED

MGNX

PCSA

RGNX

TNGX

XYLO

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BUSINESS OUTLOOK FOR FULL-YEAR 2024 CONFIRMED } Group revenues expected in the range of € 790 – 820 m (2023: € 781.4 m).&nbsp; &nbsp;R&amp;D expenditures are expected in a range of € 50 – 60 m (2023: € 64.8 m).&nbsp; &nbsp;Adjusted Group EBITDA is expected to reach € 15 – 35 m (2023: € 66.4 m).

Earnings

Guidance

Evotec Reaffirms 2024 Outlook: Revenues Of €790M-€820M, And Adjusted Group EBITDA Of €15M-€35M

Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 21 percent. This is a 0.83 percent decrease over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $203.213 million which missed the analyst consensus estimate of $208.977 million by 2.76 percent. This is a 4.88 percent decrease over sales of $213.639 million the same period last year.

Earnings Misses

Evotec Q3 2024 GAAP EPS $(0.12) Misses $(0.10) Estimate, Sales $203.213M Miss $208.977M Estimate

Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-06. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Evotec will report an earnings per share (EPS) of $-0.08.
Anticipation surrounds Evotec's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company missed EPS by $0.23, leading to a 3.63% drop in the share price the following trading session.
Here's a look at Evotec's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.06</td>
<td>-0.100</td>
<td>-0.03</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.29</td>
<td>-0.065</td>
<td></td>
<td>-0.12</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<h3>Evotec Share Price Analysis</h3>
Shares of Evotec were trading at $4.4 as of November 04. Over the last 52-week period, shares are down 50.7%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Insights Shared by Analysts on Evotec</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Evotec.
Analysts have provided Evotec with 2 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $5.9, suggesting a potential 34.09% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of 10x Genomics, BioLife Solns and Maravai LifeSciences, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus among analysts is an Outperform trajectory for 10x Genomics, with an average 1-year price target of $24.75, indicating a potential 462.5% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for BioLife Solns, with an average 1-year price target of $29.0, implying a potential 559.09% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Maravai LifeSciences, with an average 1-year price target of $10.17, suggesting a potential 131.14% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary presents essential metrics for 10x Genomics, BioLife Solns and Maravai LifeSciences, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fortrea Holdings</td>
<td>Neutral</td>
<td>-8.65%</td>
<td>$137.10M</td>
<td>-9.07%</td>
</tr>
<tr>
<td>10x Genomics</td>
<td>Outperform</td>
<td>-1.30%</td>
<td>$106.39M</td>
<td>-4.94%</td>
</tr>
<tr>
<td>BioLife Solns</td>
<td>Buy</td>
<td>-3.11%</td>
<td>$14.89M</td>
<td>-6.33%</td>
</tr>
<tr>
<td>Maravai LifeSciences</td>
<td>Neutral</td>
<td>6.51%</td>
<td>$35.13M</td>
<td>-1.79%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Evotec ranks in the middle among its peers for Consensus rating. It is at the bottom for Revenue Growth and Gross Profit, but at the top for Return on Equity.
<h3>Unveiling the Story Behind Evotec</h3>
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&amp;D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
<h3>Evotec: Financial Performance Dissected</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Evotec showcased positive performance, achieving a revenue growth rate of 6.96% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -52.13%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Evotec's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -8.96%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Evotec's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -4.51%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.47.
<a href="https://www.benzinga.com/quote/EVO/earnings">To track all earnings releases for Evotec visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Evotec's Upcoming Earnings

<ul>
<li>Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners</li>
<li>Transaction aligns with Evotec's strategic optimization efforts, concentrating resources on key growth drivers</li>
<li>New ownership committed to maintaining and growing the business</li>
</ul>

Evotec Divests API Manufacturing Site To Monacum Partners As Part Of Strategic Focus Shift; Terms Not Disclosed

U.S. stocks were lower, with the Dow Jones index falling around 300 points on Monday.
Shares of Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results.
Integra Lifesciences reported quarterly earnings of 41 cents per share which beat the analyst consensus estimate of 39 cents per share. The company reported quarterly sales of $380.83 million which beat the analyst consensus estimate of $375.78 million.
Integra LifeSciences shares jumped 24.4% to $23.96 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares jumped 43% to $66.22 after the company entered a securities purchase agreement for a PIPE investment, expected to bring in gross proceeds of $200 million.</li>
<li>Air Transport Services Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) gained 26.4% to $22.01 after the company announced it will be acquired by Stonepeak for approximately $3.1 billion, with shareholders receiving $22.50 per share in cash.</li>
<li>Xiao-I Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) rose 24.2% to $7.14. Xiao-I entered into private placement &amp; securities purchase agreement to issue, sell convertible promissory note for $2.1 million.</li>
<li>Disc Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) gained 22.9% to $57.93 after the company announced the end of its Phase 2 Bitopertin In Erythropoietic Protoporphyria meeting with the FDA. The company is aligned with the FDA across all proposed study parameters and has a clear development path to registration.</li>
<li>Globalstar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NASDAQ">GSAT</a>) gained 21.8% to $1.6800.</li>
<li>Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) rose 16% to $5.64.</li>
<li>The Chemours Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>) gained 14.6% to $20.42 after the company reported better-than-expected quarterly financial results.</li>
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) rose 13.5% to $7.61.</li>
<li>Evotec SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NYSE">EVO</a>) jumped 13.1% to $4.3850.</li>
<li>LexinFintech Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LX#NYSE">LX</a>) gained 12.8% to $3.6100.</li>
<li>Freshpet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) gained 10.9% to $148.32 after the company reported better-than-expected quarterly financial results and raised its full-year adjusted EBITDA outlook.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) rose 9.4% to $10.88.</li>
<li>Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) surged 8.1% to $48.73 after the company reported better-than-expected quarterly EPS and revenues.</li>
<li>Nextracker Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) gained 8% to $42.75.</li>
<li>Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) rose 7.5% to $7.80.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 7.5% to $1.2250.</li>
<li>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) gained 7.3% to $29.13 after it was announced that the company will join the S&amp;P MidCap 400 prior to the opening of trading on Wednesday, Nov. 6.</li>
<li>Bath &amp; Body Works, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NASDAQ">BBWI</a>) rose 7.2% to $30.99.</li>
<li>Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) gained 5.6% to $ 38.29</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713625/this-roblox-analyst-turns-bullish-here-are-top-5-upgrades-for-monday">This Roblox Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday</a></li>
</ul>

Intraday Update

AIXI

ARRY

ATSG

BBWI

CHWY

FRPT

GSAT

IART

IRON

NGNE

PSNY

PTON

YUMC

Integra LifeSciences Posts Upbeat Results, Joins Air Transport Services, Freshpet, Yum China And Other Big Stocks Moving Higher On Monday

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock rose 16.2% to $0.16 during Wednesday's after-market session. The market value of their outstanding shares is at $5.2 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 9.85% to $0.75. The market value of their outstanding shares is at $71.8 million. </li>
<li>Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) stock rose 9.45% to $301.0. The company's market cap stands at $17.6 billion. As per the press release, Q3 earnings came out today. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 8.94% to $2.8. The market value of their outstanding shares is at $22.3 million. </li>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) shares increased by 7.63% to $1.15. The market value of their outstanding shares is at $102.1 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock increased by 7.36% to $0.36. The company's market cap stands at $3.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) shares decreased by 10.9% to $0.49 during Wednesday's after-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) stock decreased by 8.17% to $3.26. The market value of their outstanding shares is at $1.1 billion. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares declined by 6.9% to $1.35. The market value of their outstanding shares is at $18.2 million. </li>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) shares declined by 6.67% to $5.18. The market value of their outstanding shares is at $719.7 million. As per the news, the Q3 earnings report came out today. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock decreased by 6.48% to $0.28. The market value of their outstanding shares is at $10.5 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) stock fell 6.39% to $0.3. The company's market cap stands at $22.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLK

BIAF

BIVI

CNSP

DBVT

ENVB

INAB

MBIO

PTPI

12 Health Care Stocks Moving In Wednesday's After-Market Session

Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) shares rose on Wednesday following news of advancements in its strategic partnership with Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), which is <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/ac41479364/evotec-and-bristol-myers-squibb-expand-proteomics-partnership" rel="noreferrer noopener">focused on developing a molecular glue-based pipeline.</a>
Significant scientific advancements are broadening the pipeline of molecular glue degraders into fields beyond oncology, leading to a $50 million program-based payment for Evotec.
Evotec and Bristol Myers Squibb began their strategic partnership in protein degradation in 2018.
In May 2022, the company extended and expanded its partnership with Bristol Myers Squibb for another 8 years. In August this year,&nbsp;Evotec announced progress in its strategic partnership with&nbsp;Bristol Myers, as performance-based and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/ac40329769/evotec-announces-strong-progress-in-strategic-protein-degradation-partnership-with-bristol-myers-" rel="noreferrer noopener">program-based achievements trigger payments totaling $75 million.</a>
Cord Dohrmann, Chief Scientific Officer of Evotec, expressed enthusiasm about the expanded partnership with Bristol Myers Squibb, highlighting its focus on addressing significant unmet medical needs beyond oncology.
This expansion also enhances the overall value of the deal through potential program-based milestones.
Also Read:<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41048867/novo-nordisk-and-evotec-collaborate-on-stem-cell-based-therapy-development" rel="noreferrer noopener"> Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development</a>
Evotec has significantly increased its efforts to develop innovative compounds from Bristol Myers Squibb&#8217;s top-tier library of cereblon E3 ligase modulators (CELMoDs).
The partnership continues to deliver on its goal by adding a diverse pipeline of novel molecular glue degraders for high-value targets, extending beyond oncology.
Dohrmann emphasized that the collaboration is creating an impressive pipeline of first-in-class products and looks forward to advancing their joint programs toward clinical validation for patient benefit.
Price Action: EVO shares are trading higher by 7.49% to $3.515 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40376143/bristol-myers-german-partner-evotec-plans-layoffs-cites-challenging-revenues-profitability" target="_blank" rel="noreferrer noopener">Bristol Myers&#8217; German Partner Evotec Plans Layoffs, Cites &#8216;Challenging Revenues, Profitability&#8217;</a></li>
</ul>

Biotech

Equities

Health Care

General

Why Is Evotec Stock Gaining Today?

WIIM

Evotec shares are trading higher after the company announced it expanded its proteomics partnership with Bristol Myers Squibb.

<ul>
<li>
Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology
</li>
<li>
Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value
</li>
</ul>

Evotec And Bristol Myers Squibb Strengthen Proteomics Partnership With $50M Payment, Expanding Molecular Glue Pipeline

Jefferies analyst Benjamin Jackson downgrades Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) from Buy to Hold and lowers the price target from $8.7 to $3.8.

Downgrades

Price Target

Analyst Ratings

Jefferies Downgrades Evotec to Hold, Lowers Price Target to $3.8

U.S. stock futures were lower this morning, with the Dow futures falling over 150 points on Monday.
Shares of The Sherwin-Williams Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) fell sharply in today's pre-market trading after Keybanc analyst Aleksey Yefremov downgraded the stock from <a href="https://www.benzinga.com/quote/SHW/analyst-ratings">Overweight to Sector Weight</a>.
Sherwin-Williams shares fell 1.4% to $366.00 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Chanson International Holding  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) shares declined 12.2% to $13.10 in pre-market trading after jumping 387% on Friday.</li>
<li>Heritage Insurance Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTG#NASDAQ">HRTG</a>) shares dipped 6.9% to $11.35 in pre-market trading after gaining around 2% on Friday.</li>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) shares fell 6.8% to $2.07 in pre-market trading after declining around 2% on Friday.</li>
<li>Stepan Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCL#NYSE">SCL</a>) shares fell 6.4% to $72.29 in pre-market trading after gaining 1% on Friday.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) shares fell 4.9% to $12.30 in pre-market trading after climbing over 4% on Friday.</li>
<li>Evotec SE  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NYSE">EVO</a>) shares declined 3.5% to $3.31 in pre-market trading after gaining 2% on Friday.</li>
<li>Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares fell 1.3% to $223.86 in pre-market trading.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/24/10/41194621/top-3-risk-off-stocks-that-may-explode-this-month"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41194621/top-3-risk-off-stocks-that-may-explode-this-month">Top 3 Risk Off Stocks That May Explode This Month</a></li>
</ul>

AAPL

CHSN

HRTG

MBLY

SIFY

Sherwin-Williams, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

On Thursday, Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) entered a technology development partnership with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/ac41039378/evotec-and-novo-nordisk-enter-into-technology-development-partnership-to-support-next-generation-" rel="noreferrer noopener">in cell therapy</a>.
Evotec and Novo Nordisk have significant expertise and a strategic focus on supporting stem cell-based therapies.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39419032/german-drug-developer-evotec-seeks-adviser-input-as-takeover-concerns-mount" rel="noreferrer noopener">German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount</a>.
To provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialization, the companies will collaborate on developing advanced technologies in support thereof.
Under the collaboration agreement, Novo Nordisk will fund technology development activities at Evotec's R&amp;D site in Göttingen, Germany and at Evotec's certified cell therapy manufacturing facility in Modena, Italy.
Novo Nordisk has the option to obtain exclusive rights to utilize the results of the collaboration for a pre-defined therapeutic area.
Evotec receives R&amp;D funding, an undisclosed upfront, and possible milestone and royalty payments.
Cord Dohrmann, Chief Scientific Officer of Evotec, said: "Cell therapies have already proven to be highly effective and have the potential to become functional cures in many disease areas. Stem cell-based cell therapy is a promising approach to modulate and scale cell therapies to ultimately provide tailor-made, off-the-shelf cell therapies at reasonable costs."
Citing Sydbank analysts, Reuters noted that Novo Nordisk's stem cell-based therapies for diabetes and cardiovascular diseases are still in the exploratory phase, and the collaboration with Evotec aims to unlock this potential further.
Reuters also highlighted Warburg Research analyst who suggested the partnership could be tied to Evotec's beta-cell implant program QR-Beta, with the initial upfront payment likely covering capacity, manpower, and a cost margin.
Price Action: EVO stock is up 4.80% at $3.49 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/41046485/whats-going-on-with-nvidia-braodcom-intel-and-other-chip-stocks-on-thursday" target="_blank" rel="noreferrer noopener">What's Going On With Nvidia, Broadcom, Intel, And Other Chip Stocks On Thursday?</a></li>
</ul>
Image via Evotec

Large Cap

Contracts

Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development

Evotec SE ((Frankfurt Stock Exchange:EVT, SDAX/TecDAX, OTC:<a href="https://www.benzinga.com/stock/EVOTF#OTC">EVOTF</a>, NASDAQ:<a href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.
Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on development of advanced technologies in support thereof.
Under the collaboration agreement, Novo Nordisk will provide funding for technology development activities at Evotec's R&amp;D site in Göttingen, Germany and at Evotec's certified cell therapy manufacturing facility in Modena, Italy. Novo Nordisk has an option to obtain exclusive rights to utilise the results of the collaboration for a pre-defined therapeutic area. Evotec receives R&amp;D funding, an undisclosed upfront and possible milestone and royalty payments.

Evotec and Novo Nordisk Collaborate to Develop Breakthrough Off-the-Shelf Cell Therapies for Future Commercialization

U.S. stock futures were lower this morning, with the Nasdaq futures falling over 80 points on Friday.
Shares of FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) fell sharply in today's pre-market trading after the company reported weaker-than-expected results for the first quarter of fiscal 2025 and lowered its full-year guidance.
FedEx reported first-quarter revenue of $21.6 billion, missing analyst estimates of $21.955 billion, according to Benzinga Pro. The company reported first-quarter adjusted earnings of $3.60 per share, missing analyst <a href="https://www.benzinga.com/news/earnings/24/09/40948046/fedex-q1-earnings-revenue-miss-eps-miss-lowered-guidance-challenging-quarter">estimates of $4.80 per share</a>.
FedEx shares dipped 13.1% to $260.92 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) shares dipped 11.3% to $6.21 in pre-market trading after jumping around 47% on Thursday.</li>
<li>Veea Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEA#NASDAQ">VEEA</a>) shares fell 7.6% to $10.22 in pre-market trading after declining around 10% on Thursday. Veea recently announced a strategic partnership with Crowdkeep to integrate their respective technologies into a singular, tailored solution to track assets, people, and conditions across a variety of use cases.</li>
<li>MillerKnoll, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) shares declined 5.4% to $25.99 in the pre-market trading session as the company reported downbeat first-quarter financial results on Thursday.</li>
<li>Adient plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADNT#NYSE">ADNT</a>) shares fell 5.1% to $21.43 in pre-market trading.</li>
<li>Frontline plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) shares declined 5% to $22.75 in pre-market trading.</li>
<li>Evotec SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NYSE">EVO</a>) slipped 5% to $3.46 in pre-market trading.</li>
<li>Hafnia Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAFN#NYSE">HAFN</a>) shares fell 4.9% to $7.34 in pre-market trading.</li>
<li>Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) shares declined 3.1% to $186.45 in pre-market trading. Lennar reported better-than-expected financial results for the third quarter. The company said it sees fourth-quarter new orders in a range of 19,000 to 19,300 and deliveries between 22,500 and 23,000. The company expects the average sales price to be approximately $425,000.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40952252/nvidia-tesla-rally-as-dow-s-p-500-surge-to-fresh-highs-after-fed-cuts-rates-fear-index-remains-in-g">Nvidia, Tesla Rally As Dow, S&amp;P 500 Surge To Fresh Highs After Fed Cuts Rates: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

ADNT

HAFN

MLKN

RZLV

VEEA

FedEx Reports Downbeat Results, Joins MillerKnoll And Other Big Stocks Moving Lower In Friday's Pre-Market Session

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evotec.com%2Fen&amp;esheet=54117658&amp;newsitemid=20240905884203&amp;lan=en-US&amp;anchor=Evotec+SE&amp;index=1&amp;md5=922f73d59e18144e2aaffd302310efe2">Evotec SE</a> ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:<a href="https://www.benzinga.com/stock/EVOTF#OTC">EVOTF</a>, NASDAQ:<a href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.x-chemrx.com%2F&amp;esheet=54117658&amp;newsitemid=20240905884203&amp;lan=en-US&amp;anchor=X-Chem&amp;index=2&amp;md5=f4e4e6e9bd55cba08baaa86d9de9e9a7">X-Chem</a>, leader in DNA-encoded library (DEL) technology, today announced a collaboration agreement focused on accelerating early-stage drug discovery.
X-Chem's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.x-chemrx.com%2Fdel-overview%2F&amp;esheet=54117658&amp;newsitemid=20240905884203&amp;lan=en-US&amp;anchor=DEL+technology&amp;index=3&amp;md5=e39b2ce8b737fcbaed7ff9160bab3493">DEL technology</a> streamlines hit finding by simultaneously screening up to billions of DNA-tagged compounds, identifying potential start points with high efficiency and precision.
In partnership with Evotec's screening platforms and capabilities, X-Chem is providing access to its DEL technology, including DELflex, a traditional experimental DEL solution, and HITMiner, a machine learning solution, leveraging high quality experimental DEL data to deliver optimal drug intervention starting points for innovative biological targets.

Evotec And X-Chem Collaborate To Accelerate Early-Stage Drug Discovery

U.S. stocks were mixed, with the Dow Jones index falling around 0.1% on Tuesday.
Shares of The Hain Celestial Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) shares gained 34.2% to $9.16 after the company reported better-than-expected fourth-quarter adjusted EPS results.
The company reported fourth quarter adjusted earnings per share of 13 cents, beating the analyst consensus estimate of 8 cents. Quarterly revenues of $418.80 million missed the street view of $421.2 million.
Hain Celestial shares jumped 34.2% to $9.16 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>ClearPoint Neuro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) jumped 12.1% to $13.11. ClearPoint Neuro announced early repayment of $10 million note.</li>
<li>Trip.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) gained 8.6% to $45.98 following second-quarter financial results.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) gained 7.1% to $3.77.</li>
<li>Stardust Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) climbed 6.7% to $8.55.</li>
<li>Ryanair Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYAAY#NASDAQ">RYAAY</a>) rose 5.5% to $110.01.</li>
<li>Soleno Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) surged 5.5% to $48.65. Soleno Therapeutics announced FDA acceptance for filing and priority review of its NDA for DCCR extended-release tablets for Prader-Willi Syndrome.</li>
<li>Energizer Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENR#NYSE">ENR</a>) gained 5.3% to $31.94 after Truist Securities upgraded the stock from Hold to Buy and raised its price target form $30 to $40.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40575289/jim-cramer-believes-in-dell-ceo-doesnt-like-b-g-foods">Jim Cramer Believes In Dell CEO, Doesn&#8217;t Like B&amp;G Foods</a></li>
</ul>

CLPT

HAIN

RYAAY

SDST

SLNO

TCOM

Hain Celestial Posts Upbeat Q4 Earnings, Joins Soleno Therapeutics, Energizer Holdings And Other Big Stocks Moving Higher On Tuesday

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) with a Buy and lowers the price target from $11 to $8.

HC Wainwright & Co. Maintains Buy on Evotec, Lowers Price Target to $8

Wednesday, Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) reported sales of $201.12 million (182.12 million euros), up from 170.28 million euros <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/ac40357790/evotec-se-reports-h1-2024-results-challenging-year-priority-reset-for-sustainable-profitable-grow" rel="noreferrer noopener">reported a year ago</a>.
The German drug maker reported an EPS loss of 54 cents, down from 8 cents a year ago.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39419032/german-drug-developer-evotec-seeks-adviser-input-as-takeover-concerns-mount" rel="noreferrer noopener">German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount</a>.
&#8220;However, H1 2024 revenues and profitability have been more challenging for the company than expected. We are operating in a more difficult market environment, most notably the slowdown of early-stage R&amp;D spending,&#8221; said Christian Wojczewski, CEO of Evotec.
&#8220;This has required us to accelerate our transformation towards sustainable profitable growth, leveraging better on our strengths, driving productivity, reducing complexity, and making the organization stronger for its next growth phase,&#8221; he added.
The company said the reset for profitable growth is on track to achieve the expected annualized adjusted EBITDA improvement of over 40 million euros starting in the second half of 2024
The company has identified a headcount reduction potential of approximately 400 roles (7% of the <a target="_blank" href="https://www.evotec.com/uploads/download-files/IR-ESG/2024/2024-08-14_Evotec_H1_Analyst-call.pdf" rel="noreferrer noopener">workforce</a>) across the global footprint and a reduction of the physical footprint by surrendering certain lease agreements.
The company plans to exit gene therapy and close a site in Orth, Austria. It&#8217;s also shutting down chemistry activities in Lyon, France, and separating a manufacturing facility in Halle/Westphalia, Germany.
On Tuesday, Evotec announced further progress in its strategic partnership with Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) to build a molecular glue-based pipeline. Performance-based and program-based achievements trigger payments of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/ac40329769/evotec-announces-strong-progress-in-strategic-protein-degradation-partnership-with-bristol-myers-" rel="noreferrer noopener">$75 million to Evotec</a>.
Outlook: Evotec expects 2024 revenues of 790 million euros-820 million euros, with adjusted EBITDA of 15 million euros-35 million euros.
Price Action: EVO stock is down 0.60% at $3.30 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40366210/metas-threads-may-soon-offer-disappearing-posts-adding-privacy-features-report" target="_blank" rel="noreferrer noopener">Meta&#8217;s Threads May Soon Offer Disappearing Posts, Adding Privacy Features: Report</a>.</li>
</ul>

Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability'

In a report released today, Benjamin Jackson CFA from Jefferies downgraded Evotec (0IRF – Research Report) to a Hold, with a price target of €6.80....

Evotec's Strategic Challenges and Uncertain Outlook Lead to Hold Rating

Kingdom Capital Advisors Q3 2024 Investor Letter

Warning: EVO is at high risk of performing badly

Warburg Research analyst Christian Ehmann maintained a Buy rating on Evotec (0IRF – Research Report) today and set a price target of €14.00. The co...

Evotec (0IRF) Receives a Buy from Warburg Research

Evotec (EVO) announced progress within the company's strategic partnership with Bristol Myers Squibb (BMY) relating to building a molecular glue-ba...

Evotec and Bristol Myers expand proteomics pact, triggers $50M payment

Evotec to sell API manufacturing facility to Monacum Partners

RBC Capital analyst Charles Weston maintained a Buy rating on Evotec (0IRF – Research Report) today and set a price target of €12.00. The company's...

RBC Capital Sticks to Its Buy Rating for Evotec (0IRF)

In a report released today, Benjamin Jackson CFA from Jefferies maintained a Hold rating on Evotec (0IRF – Research Report), with a price target of...

Jefferies Sticks to Their Hold Rating for Evotec (0IRF)

Evotec SE reports nine-month results

In a report released today, Christian Ehmann from Warburg Research maintained a Buy rating on Evotec (0IRF – Research Report), with a price target ...

Warburg Research Keeps Their Buy Rating on Evotec (0IRF)

CRSXF

ECRO

EVOTF

GTIM

NISTF

NPSCY

NVDA

RRGB

SCOR

SHTLF

UNFI

WHITF

Press Releases

Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb

Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths

Evotec Announces Change in Management Board

Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery

Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)

Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies

Evotec and Bristol Myers Squibb Expand Proteomics Partnership

Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024

Evotec Announces Sale of API Manufacturing Facility to Monacum Partners

Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

Comments

Evotec

Notizie

Ultime notizie per Evotec (NASDAQ:EVO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO